Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NovAliX and Inventiva Form a Strategic Alliance on Nuclear Receptors

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Inventiva and NovAliX announced that they have entered into a strategic alliance dedicated to the discovery of clinical candidates, targeting nuclear receptors.

After several years of successful collaboration in the field of nuclear receptors and a proven track record with three programs having reached clinical stage, Inventiva and NovAliX are now officially teaming up to establish a solid alliance to further deliver on the therapeutic promises of the nuclear receptor target class.

Through this alliance, Inventiva and NovAliX offer pharmaceutical and biotech companies a unique set of fully integrated nuclear receptor drug discovery capabilities by combining their respective in-depth expertise in structural biology, medicinal chemistry, biology, DMPK, pharmacology and safety. This alliance will leverage Inventiva’s and NovAliX’s diversified proprietary libraries in combination with complementary screening technologies (multiple biophysical techniques combined with biochemical and bio-functional assays). For the first time, pharmaceutical and biotech companies will be able to entrust their entire nuclear receptor drug discovery program from target validation to IND stage to one single experienced partner.

Pierre Broqua, CSO and co-founder of Inventiva, stated “This is a great opportunity for pharmaceutical and biotech companies wishing to engage in discovery collaborations to address this major, therapeutically relevant, target class. Based on our unique drug-discovery platform, proven track record in nuclear receptors, and our experience in managing collaborations, I strongly believe in our ability to again deliver innovative drug development candidates to our partners”.

Denis Zeyer, CEO of NovAliX, stated, “Ten years ago we built the company on the academic legacy of Pierre Chambon and Dino Moras, world class scientists, who pioneered the field of structural biology and nuclear receptors. We have turned that academic excellence into promising pharmaceutical candidates and this alliance is the opportunity to further extend that success”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Development in Preventing Macular Degeneration
Following macular degeneration insight, promising drugs to prevent vision loss have been identified.
Improving Tumour Therapy with Nanoparticles
UHN nanoparticle called PEARLs is a promising utilisation of photo-thermal therapy for cancer treatment.
New Antidepressant Treatment Discovered
Scientists have demonstrated how gene therapy could lead to new treatments for depression.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!